zodasiran Injection

Phase 3

Arrowhead Pharmaceuticals, Inc. (ARWR)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q3 '27

ARWRPhase 3$11.5B

zodasiran Injection Phase 3 Est. Readout

zodasiran Injection• Homozygous Familial Hypercholesterolemia60

Q3 2027~QConfirmedSTALE

CT.gov

00%

Competitive Landscape

0 competitors in Homozygous Familial Hypercholesterolemia

View Full Landscape

Drug Information

Target Indication

Homozygous Familial Hypercholesterolemia

Clinical Trial

NCT07037771

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

ARWR

Arrowhead Pharmaceuticals, Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

PlozasiranPhase 3

Familial Chylomicronemia

Plozasiran InjectionPhase 3

Severe Hypertriglyceridemia

ARO-CFBPhase 2

IgA Nephropathy

ARO-MMP7 Inhalation SolutionPhase 2

Idiopathic Pulmonary Fibrosis

ARO-DM1 Intravenous (IV) InfusionPhase 2

Myotonic Dystrophy 1

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts